Ann: Oral Devices and Cannabinoid Sales Update, page-17

Couldn’t disagree more. I think it demonstrates focus on where it needs to be - the upside of the med Cann business. Quite simply, why would any pharmaceutical company going down the FDA path play around with a devices business on the side?

Companies can’t make forecasts relating to cash flow until they are fact - that is what the quarterly is for, otherwise its designated as a forward looking statement. They have just said that they expect revenue higher than the previous corresponding quarter with basically no contribution from oral devices - so that is clearly the most detailed guidance they can give.

IHL when it raised money at 1 cent and went down the cannabis path was capped at less than $1m and post developing the cannabis opportunities reached a peak of almost $100m so i think you’re assertions that the Mouthguard business is important are grossly overblown - The market has always told you that and in fact when does anyone on this forum even discuss oral devices? It’s all about the med Cann business and the clinical program.

Lastly with regards to AXIM, they bought an oncology business. The new management clearly pivoted in to “wellness products” and now bought an oncology business. The two founders, George Anastassov and Lekhram Changoer are also no longer on the board post this so it seems obvious to me that they as the pioneers of the med Cann path not being there any longer tells you that AXIM is no longer interested in the space.

Ted